The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Cost-effectiveness of maintenance therapy in advanced ovarian cancer: Paclitaxel, bevacizumab, niraparib, rucaparib, olaparib, and pembrolizumab.
 
Juliet Elizabeth Wolford
No Relationships to Disclose
 
Jiaru Bai
No Relationships to Disclose
 
Lindsey E. Minion
No Relationships to Disclose
 
Robin Keller
No Relationships to Disclose
 
Ramez Nassef Eskander
Honoraria - Clovis Oncology
Speakers' Bureau - AstraZeneca/MedImmune; Clovis Oncology; Genentech/Roche
Travel, Accommodations, Expenses - AstraZeneca/MedImmune; Clovis Oncology; Genentech/Roche
 
John K. Chan
Honoraria - AstraZeneca; Clovis Oncology; Genentech/Roche; Tesaro
Consulting or Advisory Role - AstraZeneca; Biodesix; Clovis Oncology; Janssen Oncology; Mateon Therapeutics; Roche/Genentech; Tesaro
Speakers' Bureau - AstraZeneca; Clovis Oncology; Roche/Genentech; Tesaro
Research Funding - AstraZeneca (Inst); Roche/Genentech (Inst); Tesaro (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Clovis Oncology; Roche/Genentech; Tesaro
 
Bradley J. Monk
Leadership - US Oncology
Honoraria - Abbvie; Advaxis; Amgen; AstraZeneca; Bayer; Biodesix; Cerulean Pharma; Clovis Oncology; GlaxoSmithKline; Gradalis; Immunogen; Incyte; Insys Therapeutics; Janssen; Mateon Therapeutics; Merck; Myriad Pharmaceuticals; Nucana; Oxigene; Oxigene; Perthera; Pfizer; Precision Oncology; Roche/Genentech; Tesaro; Verastem; Vermillion
Consulting or Advisory Role - Abbvie; Advaxis; Amgen; AstraZeneca; Bayer; Biodesix; Cerulean Pharma; Clovis Oncology; GlaxoSmithKline; Gradalis; Immunogen; Incyte; Insys Therapeutics; Mateon Therapeutics; Merck; Myriad Pharmaceuticals; Nucana; Oxigene; Perthera; Pfizer; Precision Oncology; Roche/Genentech; Tesaro; Verastem; Vermillion
Speakers' Bureau - AstraZeneca; Clovis Oncology; Janssen; Roche/Genentech; Tesaro
Research Funding - Advaxis (Inst); Amgen (Inst); Array BioPharma (Inst); AstraZeneca (Inst); Genentech (Inst); Immunogen (Inst); Janssen (Inst); Lilly (Inst); Morphotek (Inst); Novartis (Inst); Nucana (Inst); Pfizer (Inst); Regeneron (Inst); Tesaro (Inst)
 
Krishnansu Sujata Tewari
Consulting or Advisory Role - Roche/Genentech
Speakers' Bureau - AstraZeneca; Merck; Roche/Genentech
Travel, Accommodations, Expenses - Roche/Genentech